Long-Term Debt Volume: Sangamo Therapeutics Inc. (SGMO)

Brandmark of Sangamo Therapeutics Inc. (SGMO)

Sangamo Therapeutics (SGMO) holds exclusive rights to core gene modification patents, granting the company significant pricing power over future drugs. The company is currently restructuring its operating model by implementing IT solutions for drug delivery and selling licenses to industry behemoths. The business relies on zinc finger technology, focusing on therapies for Fabry disease and the CNS. Long-term debt stands at 0.00, as reflected in the financial quote visualization on GURU.Markets.

SGMO Sangamo Therapeutics Inc.: Company Long-Term Debt in the range 07/04/2022 - 05/09/2026

Sangamo (SGMO) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price sangamo.com|SGMO - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Sangamo Therapeutics|SGMO - Enterprise Value
- balance sheet equity data:
Book Value per Share Sangamo Therapeutics|SGMO - Company Book Value|Capitalization to Book Value Ratio sangamo.com|SGMO - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Ratio Sangamo Therapeutics|SGMO - Long-Term Debt to Capital|Short-Term Debt to Capital Sangamo BioSciences|SGMO - Company Debts|Debt to Book Value Sangamo Therapeutics|SGMO - Company Long-Term Debt|Short-Term Debt Sangamo Therapeutics|Intermediate Coverage Ratio sangamo.com
- business earnings and investment ratios data:
SGMO - Net Income
Analysis of all company metrics:SGMO - sangamo.com
Core merchandise of Sangamo

Investors must evaluate the capital stability of Sangamo Therapeutics (SGMO) by balancing expansion against default risk. This metric captures obligations with maturities exceeding one year, determining financial leverage and the strategic predictability of management. An analysis of the firm's long-term borrowings allows for a comparison of the debt load against the logistics costs of valuable biomaterials. Stable financing ensures the uninterrupted operation of air delivery for samples to research centers.

Competitors of Sangamo Therapeutics (SGMO)

Company Long-Term Debts Tempus Labs TEM|QGEN - Company Long-Term Debt|Long-Term Debt Volume Ionis Pharmaceuticals, Inc. IONS|RGEN: Company Long-Term Debts|Avidity Corp (RNA) - Company Long-Term Debts|Company Long-Term Debt CRISPR Therapeutics AG|Company Long-Term Indebtedness WGS (genedx.com)|Company Long-Term Debts RARE|Beam Therapeutics Inc (BEAM) - Long-Term Indebtedness|Company Long-Term Debts SRPT (Sarepta Therapeutics Inc)|Company Long-Term Debts Twist Bioscience Corp TWST|TXG - Company Long-Term Debt|intelliatx.com (NTLA) - Company Long-Term Liabilities|Stoke Therapeutics, Inc. (STOK) - Company Long-Term Debt|Long-Term Debt BioLife Solutions Inc (BLFS)|Company Long-Term Liabilities WVE|MAZE: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities SION (Sionna Therapeutics Inc)|Amount of Long-Term Liabilities PRME|Company Long-Term Debts TSHA (Taysha Gene Therapies, Inc.)|Company Long-Term Loans and Borrowings QURE|MeiraGTx PLC - Company Long-Term Debts|Long-Term Debt REGENXBIO Corp|Solid Biosciences Inc. (SLDB) - Company Long-Term Debt|ocugen.com - Company Long-Term Loans and Borrowings|PACB (PacBio) - Company Long-Term Debts|Company Long-Term Debts Benitec Biopharma Inc|Company Long-Term Debt Design Pharma (DSGN)|RCKT: Long-Term Liabilities|Company Long-Term Debts FDMT (4D Molecular Therapeutics)|Lexeo Therapeutics Inc. (LXEO) - Long-Term Debt|KRRO: Company Long-Term Liabilities|EDIT - Company Long-Term Debts|SLN (Silence Therapeutics Inc.) - Company Long-Term Liabilities|PRQR: Amount of Long-Term Liabilities|CDXS (Codexis Inc) - Company Long-Term Debts|Nautilus Biotechnology Inc (NAUT) - Long-Term Debt Volume|Company Long-Term Debts MGX|Company Long-Term Liabilities Precision BioSciences Inc. DTIL|Company Long-Term Debt Generation Bio GBIO|Long-Term Debt Volume Boundless Bio Inc (BOLD)|XCUR - Company Long-Term Debt|Long-Term Debt Volume Imunon, Inc. IMNN|PHIO: Company Long-Term Debts|Long-Term Indebtedness Mustang Bio MBIO|Company Long-Term Debt TransCode Therapeutics Inc.|Company Long-Term Liabilities Bionano (BNGO)|Company Long-Term Debt Applied DNA Sciences (APDN)|BLUE - Long-Term Debt|Company Long-Term Debts IPA (ImmunoPrecise Antibodies Ltd.)|OMGA: Company Long-Term Indebtedness|OMIC - Company Long-Term Debt|RGLS (Regulus) - Company Long-Term Indebtedness|SYRS: Company Long-Term Debts|telesisbio.com (TBIO) - Company Long-Term Debts|Company Long-Term Debt TRACON Pharmaceuticals, Inc.|Unity Biotechnology Inc. (UBX) - Long-Term Debt Volume